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Results: Single treatments with either anti-PD-1 checkpoint-
blocking or CD133-specific T cell-recruiting antibodies had 
only very little effect on tumor growth. Hypofractionated 
tumor irradiation alone delayed tumor growth more strongly, 
but also only transiently for about 2 weeks. Hypofractionated 
tumor irradiation induced tumor-specific effector T cells. In 
accordance with this, the double combination of local 
radiotherapy and anti-PD-1 antibody caused long-lasting 
tumor regressions including some complete cures, even in 
mice with large melanomas. Moreover, the cured mice 
remained immune to subsequent rechallenge with rather high 
doses of either CD133+ or CD133– B16 melanoma cells. 
Noteworthy effects were also observed upon administration 
of the bispecific T cell-recruiting antibody into mice with 
irradiated tumors. The underlying mechanisms of these 
observations will be presented at the meeting. 
Conclusions: The study suggests that the evaluation of 
potential synergistic radiotherapy/immunotherapy 
combinations in immunocompetent mouse tumor models can 
provide crucial information for clinical trial planning. 
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High-tech solutions desperately looking for problems, or are 
we really making a difference?  
“Modern radiation oncology is a well-established, cost-
effective and essential component in the curative and 
palliative treatment of malignancy.” A statement no one can 
argue with. The challenge of individualized treatment 
optimization continuously drives research and technology, 
yet we should be careful not to get trapped in the “Cargo 
Cult Science” as described by Richard Feynman. In this 
lecture, the author - coming from a radiotherapy department 
with in its banner the vision: “to offer the optimal and most 
efficient radiation therapy tailored to the individual patient, 
through development and clinical implementation of novel 
irradiation techniques” - takes a critical view on new 
technologies in radiation oncology. New developments are 
more likely to be adopted if they improve the workflow, and 
if the benefits are more favourable, or at least equal to 
current care. However, sometimes it seems as if we are in a 
blind gallop towards increasingly more precise means of 
tumour localization and irradiation, the perception being 
that it is largely driven by vendors rather than the care 
takers’ or patients’ needs. If development moves too fast, 
the focus might be too strong on the innovation itself and less 
on the (safe) implementation. Industry funded research 
doesn’t help much, in that less favourable results do not 
always end up being published, hence inducing a strong bias 
towards a perception that improved treatment delivery 
requires high-tech solutions; whereas sometimes common 
sense might yield equivalent clinical results. Scientific and 
technological progress comes at a significant cost, and many 
concerns exist regarding the value of that progress. Within 
the current state of the economy, health care politicians face 
the difficult challenge to allow progress through efficacy and 
driven by outcomes. What’s even worse is the danger that 
too much focus on sophisticated expensive technology may 
create a double layer health care system where not all 
patients have access to the best of care. In the end what 
counts is the result, not how we got there. Does this mean 
we have to refrain from innovation? Certainly not. Indeed, 
looking back at the technological progress that has been 
realized the last decades (perhaps “century” is more apt), 
this evolution has been translated successfully into clinical 
improvements both in patient cure as well as quality of life 
(with recent developments such as IMRT, IGRT, BCRT, IGBT, 
SBRT, IMPT, etc, as a proof of concept). In conclusion, it is 
safe to state that many good technological solutions are 
being developed as we speak, the challenge is to introduce 
these innovations adapted to the radiotherapy requirements 
(the end-users) … not the other way around. 
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Human papillomavirus (HPV) infections are an essential cause 
for virtually all carcinomas of the uterine cervix and subsets 
of other anogenital, oropharyngeal and laryngeal tumors. The 
HPV aetiological contribution differs in each anatomical 
location reflecting differences in natural history and viral 
tissue tropism. Up to 99,9% of cervical, 80% of anal and 30% 
of vulvar cancers have been defined as HPV DNA positive by 
epidemiological studies. In the head-and-neck (H&N) region, 
HPV DNA positivity was detected in up to 50% of 
oropharyngeal (in Central Europe) and 35% of laryngeal 
cancers. However, recent studies on H&N cancers 
(specifically oropharyngeal cancer/cancer of the tonsil) have 
demonstrated that the presence of HPV DNA per se in 
invasive tumor tissues is insufficient proof for viral causality 
and could result in misclassification of malignant lesions and 
consequently, mistreatment of cancer patients. In addition, 
several studies have reported a better response to 
radiotherapy of HPV-driven oropharyngeal carcinomas, but 
not non-HPV-driven ones. Therefore, defining HPV-driven 
tumors by measuring markers of HPV-transformation in 
addition to HPV DNA, is crucial. Cervical squamous cell 
carcinoma (CSCC) is the best-understood model for HPV-
transformation, and up to 99% of HPV DNA positive CSSC are 
also HPV-driven. In addition to HPV DNA presence, CSCC is 
characterized by: (i) at least 1 viral genome copy present in 
each tumor cell (viral load), (ii) expression of viral oncogenes 
E6 and E7 (HPV RNA), and (iii) alteration of steady state 
levels of cellular proteins, most consistently up-regulation of 
p16INK4a. Outside of the cervix, this proof-of-principle marker 
combinations have been, to various extents, demonstrated 
for the cancer of the oropharynx, larynx, vulva and anus, 
with HPV16 being a leading transforming agent. In Central 
